Skip to main content
    T

    Telix Pharmaceuticals Limited (TLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.57
    -0.08 (-0.75%)

    Market Cap: $3.62B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(1/3)
    Avg Surprise
    -36.04%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.07
    Range$0.07 - $0.07
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.04+62.8%
    60d ago$0.01+400.0%
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$0.07
    Revenue Consensus
    $312M
    Range$276M - $348M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.09
    Range$-0.03 - $0.34
    5 analysts
    Revenue Consensus
    $764M
    Range$735M - $821M
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.09---
    Sep 26EST
    		-$0.07---
    Jun 26
    Reported Aug 19
    		$N/A$0.00N/ABeat-
    Mar 26
    Reported Mar 31
    		$N/A$-0.01N/ABeat-
    Dec 25
    Reported Feb 19
    		$0.04$0.08-48.05%Miss-33.3%
    Sep 25
    Reported Oct 14
    		$-0.09$-0.14+35.25%Beat-
    Jun 25
    Reported Aug 20
    		$0.01N/A-95.33%Miss-
    Mar 25
    Reported Apr 22
    		$0.09$0.00N/ABeat-
    Dec 24
    Reported Feb 20
    		$0.06$0.00N/ABeat-
    Sep 24
    Reported Oct 17
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDA84.92x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin3.76%Operating Margin9.71%
    ROE7.36%ROIC-0.73%
    Financial Health
    Debt/Equity0.73xInterest Coverage0.86x
    Current Ratio2.01xQuick Ratio1.85x
    Trading Statistics
    Beta0.56Avg Volume436.29K
    52-Week High$13.1152-Week Low$6.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.90
    SMA 20$11.18
    SMA 50$11.52
    SMA 200$9.79
    EMA 10$10.93
    EMA 20$11.12
    EMA 50$11.22
    EMA 200$10.74

    MACD

    Line: -0.21Signal: -0.16Hist: -0.05

    ADX

    ADX: 16.6+DI: 26.1-DI: 43.7

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$11.73

    Bollinger Bands

    Upper Band$12.16
    Lower Band$10.19
    %B Position1758%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    42.0

    Momentum Oscillators

    Stoch %K21.6
    Stoch %D37.6
    Williams %R-89.3
    ROC (10d)-1.4%
    Momentum-0.15
    CCI (20d)-123.9
    MFI (14d)48.8

    Volatility Measures

    ATR (14d)$0.41(3.8%)
    StdDev (20d)0.49
    Hist Vol54.9%(High)

    Volume Flow

    VWAP$10.53
    OBV773.3K
    AD Line4.2M
    CMF (20d)0.118

    Volume Metrics

    Avg Vol (20d)427.2K
    Vol Ratio0.5x
    VWMA (20d)$11.25

    Pivot Points

    R3$10.90
    R2$10.84
    R1$10.74
    Pivot Point$10.68
    S1$10.58
    S2$10.52
    S3$10.42

    Advanced Oscillators

    TSI-8.57
    Ultimate Osc46.5
    KST-68.56

    Financial Data

    QuarterJun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021Jun 2021Dec 2020
    Total Revenue$691.36M$620.44M$593.11M$594.24M$188.96M$281.71M$220.83M$136.05M$24.05M$4.69M$2.91M$3.61M
    Cost of Revenue$334.74M$293.02M$304.77M$208.45M$65.08M$57.74M$130.02M$91.16M$39.62M$23.54M$14.09M$11.86M
    Gross Profit$356.63M$327.42M$288.34M$385.80M$123.88M$223.97M$90.81M$44.89M$-15,572,000$-18,858,000$-11,176,000$-8,253,000
    Operating Expenses$376.53M$317.60M$272.56M$317.42M$110.13M$203.90M$59.37M$54.59M$47.92M$31.06M$20.42M$20.89M
    R&D$179.34M$134.56M$123.96M$75.25M$45.78M$98.40M$30.45M$33.01M$24.84M$20.46M$13.67M$14.48M
    SG&A$0$0$72.51M$63.66M$57.99M$43.87M$23.32M$36.41M$12.72M$7.09M$4.37M$15.30M
    Operating Income$-19,908,786$9.82M$15.79M$68.38M$13.75M$-15,598,000$31.44M$-9,704,000$-63,494,000$-49,916,000$-31,600,000$-29,144,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$7.03M$11.68M$3.92M$16.52M$4.94M$548,000$442,000$268,000$138,000$104,000$85,000$940,000
    Income Before Tax$42.36M$-645,299$-7,347,818$46.91M$9.14M$15.39M$-12,300,000$-27,919,000$-70,703,000$-61,993,000$-37,046,000$-35,157,000
    Income Tax Expense$-13,153,760$6.61M$-3,865,353$8.67M$-2,537,000$-4,144,000$2.02M$5.27M$188,000$-13,997,000$-4,532,000$-8,571,000
    Net Income$55.51M$-7,252,866$-3,482,464$38.24M$11.68M$19.53M$-14,320,000$-33,188,000$-70,891,000$-47,996,000$-32,514,000$-26,586,000
    EBITDA$17.30M$28.92M$14.25M$82.78M$40.29M$22.99M$-8,573,000$-24,993,000$-67,826,000$-59,261,000$-33,877,000$-31,670,000
    EBIT$-19,908,786$11.03M$-1,762,504$78.46M$36.63M$20.90M$-11,858,000$-27,651,000$-70,565,000$-61,889,000$-36,692,000$-34,217,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLX

    News

    Dr Boreham’s Crucible: Telix bets big on ITM as radiopharma consolidation gathers pace

    Telix Pharmaceuticals (ASX:TLX) is proposing a US$2.35 billion merger with German radiopharmaceutical company ITM...

    Stockhead•10/15/26•Somewhat-Bullish

    Telix Pharmaceuticals And 2 Other Australian Insider Owned Growth Stocks

    This article highlights three Australian growth stocks with high insider ownership and strong growth potential: Telix Pharmaceuticals (ASX:TLX), Codan (ASX:CDA)...

    Simply Wall Street•10/14/26•Somewhat-Bullish

    First U.S. Brain Scan Doses Could Be A Game Changer For Telix Pharmaceuticals (ASX:TLX)

    Telix Pharmaceuticals has commenced U.S. dosing of Pixclara for glioma imaging and secured FDA Fast Track designation for its BiPASS prostate cancer study. These advancements...

    Simply Wall Street•10/13/26•Somewhat-Bullish

    Profound Medical signs Telix prostate imaging agreement

    Profound Medical has entered a co-education agreement with Telix Pharmaceuticals to advance imaging-informed prostate care. The collaboration will focus on educating physicians about Telix's PSMA-PET imaging...

    grafa.com•10/9/26•Bullish

    Telix Pharmaceuticals (ASX:TLX) Could Be 35% Below Fair Value On Pixclara Launch

    Telix Pharmaceuticals has started dosing patients in the U.S. with its FDA-approved brain cancer diagnostic, Pixclara, following its FDA Fast Track status for prostate cancer imaging. Despite a 39.7% year-to-date gain...

    Simply Wall Street•10/7/26•Bullish

    TLX Valuation and Fair Value

    Forward P/E
    140.8x
    EV/EBITDA
    84.9x
    P/B
    5.4x
    See GNG's fair value

    TLX Profitability: Margins, ROIC and FCF

    Gross margin
    52.1%
    Operating margin
    9.7%
    Net margin
    3.8%
    ROIC
    -0.7%
    ROE
    7.4%
    FCF margin
    -5.8%

    TLX Competitors

    CompanyTicker
    Envista Holdings CorpNVST
    National HealthCare CorporationNHC
    Tango Therapeutics IncTNGX
    Organon & CoOGN
    Catalyst Pharmaceuticals IncCPRX
    iRhythm Technologies IncIRTC
    Edgewise Therapeutics IncEWTX
    Veracyte IncVCYT

    Sector: Healthcare

    TLX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TLX Bull Case vs Bear Case

    Bull case

    • TLX grew quarterly revenue 22.3% year over year.
    • 100.0% of TLX's analyst ratings are Buy or Strong Buy.

    TLX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 6 quarters (50.0%)
    Average surprise
    -36.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About TLX

    Does TLX pay dividends?

    Telix Pharmaceuticals Limited (TLX) does not currently pay a regular dividend.

    What is TLX's market cap?

    Telix Pharmaceuticals Limited (TLX) has a market capitalization of $3.62B with a current stock price of $10.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In